Masimo Corp - MASI STOCK NEWS

Masimo (NASDAQ: MASI) is set to participate in the Piper Sandler 33rd Annual Healthcare Conference on November 30, 2021, at 2:00 p.m. Eastern Time. The event will feature a live webcast available on the Masimo website, with a replay option for later viewing. Masimo is recognized for its advanced medical monitoring technologies and aims to enhance patient care while reducing associated costs. Its pulse oximetry technology is utilized in top hospitals globally, proving a significant impact on patient outcomes.

Masimo (NASDAQ: MASI) released findings from a study published in Frontiers in Neurology demonstrating that its SedLine^® Brain Function Monitoring can significantly reduce the incidence of postoperative delirium (POD) in carotid endarterectomy patients. In a trial with 255 participants, those monitored with SedLine exhibited a 7.87% POD rate compared to 28.91% for standard monitoring (p < 0.01). The study highlights the potential for improved patient outcomes through enhanced anesthesia management using multiple EEG parameters.

Masimo (NASDAQ: MASI) will participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 4:00 p.m. Eastern Time. A live webcast can be accessed via the Masimo website, with a replay available post-event. Masimo is known for its innovative medical technologies including pulse oximetry that enhances patient monitoring. Established in 1995, their SET® technology is used globally, improving outcomes and reducing healthcare costs. For more details, visit www.masimo.com.

Masimo (NASDAQ: MASI) announced a study published in Frontiers in Aging Neuroscience indicating that its Root® monitoring platform could enhance postoperative cognitive function in elderly patients undergoing spinal surgery. The study involved 26 patients, showing that the intervention group managed with a multimodal algorithm had a higher mean postoperative MoCA score (24.80) compared to the control group (22.56). The research suggests that the algorithm's precision in monitoring could reduce the risk of postoperative neurocognitive disorder.

Masimo (NASDAQ: MASI) has launched Dual SET® Pulse Oximetry for Root®, enhancing critical congenital heart disease (CCHD) screening. The CE-marked Masimo SET® MOC-9® module and the Eve™ application enable simultaneous pre- and post-ductal oxygen saturation measurements, improving newborn screening efficiency. CCHD affects 2.5 to 3 newborns per 1,000 births, necessitating early detection to reduce mortality and morbidity. Masimo's technology has shown increased screening sensitivity, enhancing newborn care and clinical workflows, although the new products are not yet FDA cleared for the U.S.

Masimo (NASDAQ: MASI) reported Q3 2021 financial results, highlighting product revenue of $307.4 million, a growth of 10.5% from Q3 2020. GAAP net income reached $57.8 million, or $1.00 per diluted share, up from $49.4 million, or $0.85 per share in the previous year. The company maintained strong operational performance with GAAP operating margins of 22.0% and non-GAAP margins at 23.0%. For full-year 2021, Masimo revised its guidance to a total revenue of $1.230 billion, representing a projected growth of 7.5%.

Masimo (NASDAQ: MASI) presented findings at ANESTHESIOLOGY 2021, demonstrating the efficacy of its PVi® technology in managing fluid administration during major oncosurgery. Researchers from Rajiv Gandhi Cancer Institute found that patients guided by PVi received significantly less fluid and exhibited fewer B-lines, indicators of extravascular lung water (EVLW), without a decrease in postoperative oxygenation compared to those using conventional CVP methods. These results highlight PVi's potential for enhanced patient care in surgical settings.

Masimo (NASDAQ: MASI) will announce its third quarter 2021 financial results on October 26, 2021, after market close. The results will be discussed in a conference call scheduled for 1:30 p.m. PT (4:30 p.m. ET), featuring CEO Joe Kiani and CFO Micah Young. Masimo is a renowned medical technology company focused on noninvasive monitoring technologies aimed at improving patient outcomes and reducing costs. The company’s drive for innovation has made its technologies integral in leading hospitals globally.

Masimo's Patient SafetyNet™ is enhancing healthcare efficiency at University Hospitals in Cleveland by tackling nurse burnout and boosting workflows. Amid rising nursing turnover—with 80% of hospitals reporting increased rates—this innovative system significantly decreases the time between obtaining and documenting patient vital signs from over 60 minutes to less than 5 minutes, saving one FTE per shift. Clinical studies support the system's effectiveness in improving patient monitoring and outcomes, marking a pivotal step in addressing nursing shortages exacerbated by the COVID-19 pandemic.